A Single Center Clinical Analysis of Children with High-risk Neuroblastoma

Overview

Journal Oncotarget

Specialty Oncology

Date 2017 Apr 21

PMID 28423674

Citations 4

Authors

Xiangdong Tian

Yanna Cao

Jingfu Wang

Jie Yan

Yao Tian

Zhongyuan Li

Huijuan Wang

Xiaofeng Duan

Yan Jin

Qiang Zhao

Affiliations

Soon will be listed here.

Abstract

Methods: This study enrolled patients with high-risk neuroblastoma between 2009 and 2014 in Department of Pediatric Oncology of Tianjin Medical University Cancer Institute and Hospital. The clinical characteristics of patients were illustrated and surgery extent was evaluated by the impact on survival rate.

Results: The 3-year overall survival (OS) and progression-free survival (PFS) were 56.2% and 50.5%, respectively. LDH (P<0.001), bone marrow metastasis at time of diagnosis (P=0.001), bone marrow negative after neoadjuvant chemotherapy (P<0.001), radiotherapy (P<0.001) were significant predictors of OS and PFS. And surgery extent had no impact on the enhancement of high-risk neuroblastoma patients in short time.

Conclusions: This study showed no substantial survival benefit in patients with high-risk NB undergoing gross total tumor resection. Multidisciplinary intensive treatment was essential, especially for patients received subtotal tumor resection. Longer term follow-up is needed to survey complications in surviving patients who received intensive chemotherapy and radiotherapy.

Citing Articles

Association of Image-Defined Risk Factors with Clinical, Biological Features and Outcome in Neuroblastoma.

Laura B, Radu B, Patricia C, Andreea M Children (Basel). 2022; 9(11).

PMID: 36360435 PMC: 9688519. DOI: 10.3390/children9111707.

[Clinical efficacy of combined therapy in children with stage 4 neuroblastoma].

Liang W, Ye X, Zhong G, Chen J, Dai K, Cheuk K Zhongguo Dang Dai Er Ke Za Zhi. 2022; 24(7):759-764.

PMID: 35894190 PMC: 9336616. DOI: 10.7499/j.issn.1008-8830.2203049.

The Significance of Histopathologic Assessment in Bone Marrow Disease in Neuroblastoma.

Ekmekci S, Ince D, Olgun N, Ozer E Turk Patoloji Derg. 2021; 38(2):99-105.

PMID: 34558657 PMC: 9999680. DOI: 10.5146/tjpath.2021.01556.

Advances in the Surgical Treatment of Neuroblastoma.

Luo Y, Cui X, Yang L, Zhang D, Wang J Chin Med J (Engl). 2018; 131(19):2332-2337.

PMID: 30246719 PMC: 6166470. DOI: 10.4103/0366-6999.241803.

References

De Ioris M, Crocoli A, Contoli B, Garganese M, Natali G, Toma P . Local control in metastatic neuroblastoma in children over 1 year of age. BMC Cancer. 2015; 15:79. PMC: 4349468. DOI: 10.1186/s12885-015-1082-7. View

Brodeur G, Seeger R, Schwab M, Varmus H, Bishop J . Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science. 1984; 224(4653):1121-4. DOI: 10.1126/science.6719137. View

Matthay K, Reynolds C, Seeger R, Shimada H, Adkins E, Haas-Kogan D . Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study. J Clin Oncol. 2009; 27(7):1007-13. PMC: 2738615. DOI: 10.1200/JCO.2007.13.8925. View

Tsuchida Y, Yokoyama J, Kaneko M, Uchino J, IWAFUCHI M, Makino S . Therapeutic significance of surgery in advanced neuroblastoma: a report from the study group of Japan. J Pediatr Surg. 1992; 27(5):616-22. DOI: 10.1016/0022-3468(92)90461-f. View

Ducassou A, Gambart M, Munzer C, Padovani L, Carrie C, Haas-Kogan D . Long-term side effects of radiotherapy for pediatric localized neuroblastoma : results from clinical trials NB90 and NB94. Strahlenther Onkol. 2015; 191(7):604-12. DOI: 10.1007/s00066-015-0837-z. View

Seeger R, Villablanca J, Matthay K, Harris R, Moss T, Feig S . Intensive chemoradiotherapy and autologous bone marrow transplantation for poor prognosis neuroblastoma. Prog Clin Biol Res. 1991; 366:527-33. View

Sultan I, Ghandour K, Al-Jumaily U, Hashem S, Rodriguez-Galindo C . Local control of the primary tumour in metastatic neuroblastoma. Eur J Cancer. 2009; 45(10):1728-32. DOI: 10.1016/j.ejca.2009.04.021. View

Matthay K, Atkinson J, Stram D, Selch M, Reynolds C, Seeger R . Patterns of relapse after autologous purged bone marrow transplantation for neuroblastoma: a Childrens Cancer Group pilot study. J Clin Oncol. 1993; 11(11):2226-33. DOI: 10.1200/JCO.1993.11.11.2226. View

Moroz V, Machin D, Faldum A, Hero B, Iehara T, Mosseri V . Changes over three decades in outcome and the prognostic influence of age-at-diagnosis in young patients with neuroblastoma: a report from the International Neuroblastoma Risk Group Project. Eur J Cancer. 2010; 47(4):561-71. DOI: 10.1016/j.ejca.2010.10.022. View

10.

Baade P, Youlden D, Valery P, Hassall T, Ward L, Green A . Population-based survival estimates for childhood cancer in Australia during the period 1997-2006. Br J Cancer. 2010; 103(11):1663-70. PMC: 2994235. DOI: 10.1038/sj.bjc.6605985. View

11.

Matthay K . Neuroblastoma: biology and therapy. Oncology (Williston Park). 1998; 11(12):1857-66; discussion 1869-72, 1875. View

12.

Brodeur G, Pritchard J, Berthold F, Carlsen N, Castel V, Castelberry R . Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol. 1993; 11(8):1466-77. DOI: 10.1200/JCO.1993.11.8.1466. View

13.

Ikeda H, August C, Goldwein J, Ross 3rd A, DAngio G, Evans A . Sites of relapse in patients with neuroblastoma following bone marrow transplantation in relation to preparatory "debulking" treatments. J Pediatr Surg. 1992; 27(11):1438-41. DOI: 10.1016/0022-3468(92)90195-d. View

14.

ADAMS G, Shochat S, SMITH E, Shuster J, JOSHI V, Altshuler G . Thoracic neuroblastoma: a Pediatric Oncology Group study. J Pediatr Surg. 1993; 28(3):372-7; discussion 377-8. DOI: 10.1016/0022-3468(93)90234-c. View

15.

Haase G, OLeary M, Stram D, Lukens J, Seeger R, Shimada H . Pelvic neuroblastoma--implications for a new favorable subgroup: a Children's Cancer Group experience. Ann Surg Oncol. 1995; 2(6):516-23. DOI: 10.1007/BF02307085. View

16.

Brodeur G, Nakagawara A . Molecular basis of clinical heterogeneity in neuroblastoma. Am J Pediatr Hematol Oncol. 1992; 14(2):111-6. DOI: 10.1097/00043426-199205000-00004. View

17.

Canete A, Jovani C, Lopez A, Costa E, Segarra V, Fernandez J . Surgical treatment for neuroblastoma: complications during 15 years' experience. J Pediatr Surg. 1998; 33(10):1526-30. DOI: 10.1016/s0022-3468(98)90490-0. View

18.

Kushner B, Wolden S, LaQuaglia M, Kramer K, Verbel D, Heller G . Hyperfractionated low-dose radiotherapy for high-risk neuroblastoma after intensive chemotherapy and surgery. J Clin Oncol. 2001; 19(11):2821-8. DOI: 10.1200/JCO.2001.19.11.2821. View

19.

Yeung F, Chung P, Tam P, Wong K . Is complete resection of high-risk stage IV neuroblastoma associated with better survival?. J Pediatr Surg. 2015; 50(12):2107-11. DOI: 10.1016/j.jpedsurg.2015.08.038. View

20.

Park J, Eggert A, Caron H . Neuroblastoma: biology, prognosis, and treatment. Pediatr Clin North Am. 2008; 55(1):97-120, x. DOI: 10.1016/j.pcl.2007.10.014. View